Bullish Case: Goldman Sachs' recommendation of a 70% return on Geron speaks favourably of the possibly growing confidence in the company's potential [Observer][kalkinemedia.com].
Show historical bullish cases
April 25, 2023: High interest from institutional investors [beststocks.com], potential for successful blood cancer therapy imetelstat [Helium], and AI price forecast predicts growth [Helium].
May 05, 2023: Institutional investors' interest, potential success of imetelstat[Helium], and positive AI price forecast[Helium] signal growth opportunities for Geron.
May 23, 2023: Institutional investors show interest, imetelstat's potential success, and positive AI price forecast indicate growth opportunities for Geron[Helium][Helium].
June 17, 2023: GERN trading at high level from past years [Helium-11] and has shown growth opportunities due to imetelstat potential [Helium-17].
July 15, 2023: Geron's stock (GERN) has shown notable growth over the past two years, trading 157.6% higher [Helium] and showing significant upward mobility from one [Helium] to sixty days ago [Helium].
August 04, 2023: Despite minor fluctuations, Geron has demonstrated strong growth, especially on a yearly basis [Helium][Helium][Helium] and the development of imetelstat continues to generate promising results [Helium][Helium][Helium][Helium][Helium].
August 25, 2023: Beneficial effects of zingerone and potential application in clinical practice show growth opportunities for Geron, fuelled by strong institutional ownership interest[NCBI][beststocks.com][NCBI].
Bearish Case: The present uncertain climate surrounding US leadership due to dementia concerns highlighted by RAND Corp [Alternet] and contextually concurrent with Geron's tied biotech endeavours could pose risks.
Show historical bearish cases
April 25, 2023: Drop in short interest [beststocks.com], insider trading activity raises concern [beststocks.com], and success solely depends on imetelstat's market reception [Helium].
May 05, 2023: Insider trading activity raises concerns[Helium], and Geron's future strongly depends on imetelstat's market reception[Helium].
May 23, 2023: Insider trading activity raises concerns, and Geron's future strongly depends on imetelstat's market reception[Helium][Helium].
June 17, 2023: Insider trading activity concern [Helium-19], and GERN depends on imetelstat success [Helium-21].
July 15, 2023: Despite upward trends, Geron faced a 6.4% decrease from five years ago [Helium], coupled with potential uncertainty reflected in 30th percentile in average implied volatility [Helium].
August 04, 2023: Market implied volatility for Geron sits at a lower percentile [Helium] and future success hinges heavily on imetelstat's successful market reception [Helium][Helium][Helium][Helium][Helium][Helium].
August 25, 2023: Given the recent decreasing trend in GERN's performance, the company faces challenges if imetelstat does not succeed[Helium][Helium][Helium][Helium].
Takeaway: Continued close monitoring of the development of imetelstat and US gerontocracy scenarios is crucial for potential investors given both the strong forecasted upside and the potential risks [Helium-44].
Show historical takeaways
April 25, 2023: Geron's future and stock price largely depend on imetelstat's success, and investors should closely monitor its clinical progress [Helium].
May 05, 2023: Geron's future and stock price pivot on imetelstat's success; investors should monitor its clinical progress closely[Helium].
May 23, 2023: Monitor Geron's clinical progress with imetelstat for potential growth, but remain cautious about insider trading activity[Helium][Helium].
June 17, 2023: Monitor imetelstat development cautiously and consider GERN's dependency on its success for future investments [Helium].
July 15, 2023: Geron's future strongly hinges on imetelstat's success and market reception, thereby making careful monitoring of its clinical progress imperative for potential investors [Helium].
August 04, 2023: The future of Geron is intrinsically tied to the market success of imetelstat and its ongoing clinical progress needs close monitoring [Helium][Helium][Helium][Helium][Helium].
August 25, 2023: Geron's future heavily depends on the success of imetelstat. Continual monitoring of the drug's progress is crucial for potential investors, intermingling bullish elements of the stock's growth prospects and possible bearish undertones[Helium][Helium][Helium][Helium][Helium][Helium].
Potential Outcomes:
1. Successful imetelstat development leads to soaring Geron stock, estimated probability: 65% [Helium-30]. The stock's bull run has been linked to the positive advancements of imetelstat drug previously.
2. Imetelstat encounters setbacks, causing Geron's stock to plummet, estimated probability: 35% [Helium-37]. Past declines show that Geron's heavy reliance on imetelstat can swing the other way if the drug's progress is uncertain.
September 15, 2023
[AAL] American Airlines (0.73)
[UAL] United Airlines (0.71)
[ASML] New York Shares (0.68)
[HSBC] HSBC (0.68)
[MOMO] Hello (0.65)
[SPHD] Invesco S&P 500 High Dividend Low Vol (-0.01)
[ORGN] Origin Materials (-0.01)
[BHF] Brighthouse Financial (0.01)
[NVCR] NovoCure (0.02)
[SUI] Sun Communities (0.02)
[DWAC] Digital World Acquisition (-0.39)
[CGC] Canopy Growth (-0.41)
[MOS] Mosaic (-0.43)
[DG] Dollar General (-0.46)
[BNTX] BioNTech SE (-0.48)
